Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

To access The New England Journal of Medicine publication on the interim results from the ANNEXA-4 study of andexanet, visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1607887 and NEJM ANNEXA-4 Supplement

Webcast ImageWebcast
Portola Pharmaceuticals, Inc. at the Oppenheimer’s 27th Annual Healthcare Conference (Replay)
03/22/17 at 1:35 p.m. ET
Portola Pharmaceuticals, Inc. at the Oppenheimer’s 27th Annual Healthcare Conference
Wednesday, March 22, 2017 1:35 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Portola Pharmaceuticals, Inc. at the Oppenheimer’s 27th Annual Healthcare Conference
Wednesday, March 22, 2017 1:35 p.m. ET
LocationNew York, NY

Portola Pharmaceuticals, Inc. at the Cowen and Company’s 37th Annual Health Care Conference
Tuesday, March 7, 2017 9:20 a.m. ET
LocationBoston, MA

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$38.61
Change (%) Stock is Up 0.10 (0.26%)
Volume277,921
Data as of 03/23/17 11:59 a.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>

Recent NewsMore >>
DateTitle 
03/07/17Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17
SOUTH SAN FRANCISCO, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that new data from the pivotal Phase 3 APEX Study of the Company’s investigational drug betrixaban will be presented in a poster session at the upcoming American College of Cardiology’s (ACC) 66th Annual Scientific Session & Expo, which is taking place from March 17-19 at the Walter E. Washington Convention Center in Washington, D.C. Additionally, clinical data on bet... 
Printer Friendly Version
03/01/17Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March: Cowen and Company’s 37th Annual Health Care Conference on Tuesday, March 7, 2017, at 9:20 a.m. Eastern Time in Boston. Oppenheimer’s 27th Annual Healthcare Conference on Wednesday, March 22, 2017, at 1:35 p.m. Eastern Time in New York. Both presentations will be web... 
Printer Friendly Version
02/28/17Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today provided a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2016. “We are working towards gaining approval of both betrixaban, our investigational oral Factor Xa inhibitor, and andexanet alfa, our investigational antidote for oral Factor Xa inhibitors, in the United States and Europe ove... 
Printer Friendly Version
02/21/17Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and year ended December 31, 2016, and provide a general business overview on Tuesday, February 28, 2017, at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Tuesday, February 28, 2017, at 4:30 p.m. Eastern Time, can be accessed by ph... 
Printer Friendly Version
02/08/17FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
PDUFA Date of June 24, 2017 Under Priority Review SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) has informed the Company, as part of its mid-cycle review, that it does not plan to hold an Advisory Committee meeting for Portola’s New Drug Application (NDA) for betrixaban. Betrixaban is an oral, once-daily Factor Xa inhib... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.